Gene

HDAC9

histone deacetylase 9

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HDAC9 Overexpression2
HDAC Inhibitor REC-2282	Malignant Esophageal Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID9855 In 62 esophageal carcinoma tumor samples, HDAC1 expression was found to considerably increase by 82% compared to adjacent non-tumor tissues with (18.2%) and identified as HDAC1 positive. HDAC1 positiv… (full text at CIViC) PMID 31908417 · Zhu et al., 2019 · Open in CIViC	civic
Panobinostat + Trichostatin A + VorinostatSubstitutes	Malignant Breast Neoplasm	Predictive	B	Supports Resistance	3	submitted	EID9230 As basal breast cancers display one of the most aggressive phenotypes in cell lines and commonly indicate poor prognosis in patients, assessing HDAC9’s variability among different cell types may evinc…

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved20 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
CPTAC-Brain, Head and Neck, Kidney, Lung, Pancreas, Uterus CPTAC-3	unmapped	Ssm

Literature

Data not yet available

No publication linked to this gene yet.